Company intelligence / Profile preview

Idenix Pharmaceuticals

Cambridge, Massachusetts, United Statesmerck.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Idenix developed a portfolio of small-molecule antiviral drug candidates targeting hepatitis C and other viral infections. Its most advanced program at the time of Merck’s acquisition was IDX21437, a nucleotide polymerase inhibitor for HCV in early clinical trials. The company also had additional preclinical and discontinued programs targeting hepatitis B and HIV. No products reached commercialization before the company was acquired by Merck & Co.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

samatasvir

Phase 2

Indications: Hepatitis C virus infection

3 more assets in the full pipeline.

Request access →

Partnerships

Novartis Pharma AG

Beyond the preview

Go deeper on Idenix Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Idenix Pharmaceuticals.

Explore the full profile